NCT04144751 is a clinical trial of Blood Sample Collection in Colorectal Cancer, sponsored by Exact Sciences Corporation.

Who is sponsoring NCT04144751?

NCT04144751 is sponsored by Exact Sciences Corporation.

What drugs are being tested in NCT04144751?

Interventions in NCT04144751: Blood Sample Collection.

What condition does NCT04144751 study?

NCT04144751 studies Colorectal Cancer.

Is NCT04144751 still recruiting?

NCT04144751 is currently completed. Last updated 28 September 2023.

Last reviewed 2023-09-28 · How we verify

NCT04144751

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Blood Collection Sub-Study of Exact Sciences Protocol 2019-01: "Clinical Validation of an Optimized Multi-Target Stool DNA (Mt-sDNA 2.0) Test, For Colorectal Cancer Screening BLUE-C"

Completed Last updated 28 September 2023

What this trial tests

trial testing Blood Sample Collection in Colorectal Cancer in 23,494 participants. Completed in 30 March 2023.

Timeline

15 November 2019

Primary endpoint
30 March 2023

30 March 2023

Quick facts

Lead sponsor	Exact Sciences Corporation
Status	Completed
Study type	OBSERVATIONAL
Enrollment	23,494
Start date	15 November 2019
Primary completion	30 March 2023
Estimated completion	30 March 2023
Sites	194 locations across United States

Drugs / interventions tested

Blood Sample Collection — full drug profile →

Conditions studied

Colorectal Cancer — all drugs for Colorectal Cancer →

Sponsor

Exact Sciences Corporation

Who can join

40 and older, any sex, with Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of this sub-study, 2019-01B, is to collect blood specimens for research use in the development and validation of a blood-based test for colorectal cancer (CRC).

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Cell-free DNA approaches for cancer early detection and interception.
Medina JE, Dracopoli NC, Bach PB, Lau A, et al · · 2023 · cited 64× · PMID 37696619 · DOI 10.1136/jitc-2022-006013
Research progress and applications of epigenetic biomarkers in cancer.
Gao J, Shi W, Wang J, Guan C, et al · · 2024 · cited 10× · PMID 38681199 · DOI 10.3389/fphar.2024.1308309
Current Progress in Clinical Research in Secondary Prevention and Early Detection of Colorectal Cancer.
Partyka O, Pajewska M, Czerw A, Deptała A, et al · · 2025 · cited 2× · PMID 39941735 · DOI 10.3390/cancers17030367

Verify or expand the search:

Other trials of Blood Sample Collection

Trials testing the same drug.

NCT07436637 — Guardant Shield Colorectal Cancer Screening · NA · not yet recruiting
NCT07054346 — Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617 · Phase 1 · recruiting
NCT06695494 — Enabling Genomic Testing in Cancer of Unknown Primary · recruiting
NCT07405515 — Pathophysiology of Dysautonomia and Postural Tachycardia Syndrome (POTS) in Post-viral Syndromes and COVID-19 · NA · active not recruiting
NCT05487248 — A Study of On-treatment ctDNA Changes in Chemo-refractory Colorectal Cancer Patients · NA · active not recruiting

Other recruiting trials for Colorectal Cancer

Currently open trials in the same condition.

NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes · recruiting
NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes · recruiting

Other Exact Sciences Corporation trials

Trials by the same sponsor.

NCT05246839 — Informed Choice - Compass · terminated
NCT05210283 — CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer · active not recruiting
NCT04473625 — Stool Collection Sub-Study of Exact Sciences Protocol 2018-01 · completed
NCT04395391 — Home Usability Study of the SARS-CoV-2 (COVID-19) Test · completed
NCT04213326 — Detecting Cancers Earlier Through Elective Plasma-based CancerSEEK Testing · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04144751 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Exact Sciences Corporation
Last refreshed: 28 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04144751.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing